Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials indus…
$15.47+2.18%
报价 2026-11-06
市值
$10.48B
EV
$13.7B
PE (TTM)
30.9x
预期 PE (FY2026)
18.9x
52 周区间距高点 -10.5%
$7.41$17.29
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.0x | 0.82 → 0.89（1.1x） | 17.4 |
| FY+32028-12 | 1.1x | 0.82 → 0.97（1.2x） | 15.9 |
毛利率 32% · TTM 收入 $6636M · 基数 EPS 0.82（调整后）
电话会信号
辅助标签Q3 20262026-10-28
需求加速AI 词频高上调指引
指引 上调
信心 4
分析师 4
“We believe improving execution and stronger end markets provide a foundation for sustained revenue growth.”
原文引用（2）
- 需求加速：The recovery that began in Q2 continue to build in Q3 and importantly has broadened.
- 上调指引：we are raising our full year 2026 organic revenue adjusted EPS and free cash flow guidance
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| AVTRAvantor, Inc. | $10.48B | +2.2% | +2.2% | 31.5% | 30.9x | 15.1x | 23.9x | |
| BAXBaxter International Inc. | $13.34B | +0.5% | +5.8% | 33.4% | – | 25.2x | 13.3x | |
| RGENRepligen Corporation | $11.09B | +3.0% | +15.8% | 53.1% | 233.1x | 56.2x | 87.9x | |
| MOHMolina Healthcare, Inc. | $10.91B | -3.5% | -0.6% | 8.2% | – | 31.2x | 45.8x | |
| BIOBio-Rad Laboratories, Inc. | $10.25B | +3.4% | +0.1% | 51.9% | 9.4x | 9.6x | 27.2x | |
| HSICHenry Schein, Inc. | $9.59B | +0.9% | +5.8% | 31.8% | 24.9x | 12.7x | 17.8x | |
| ATRAptarGroup, Inc. | $9.03B | -1.1% | +8.7% | 27.8% | 22.0x | 11.1x | 25.3x | |
| GRFSGrifols, S.A. | $7.13B | -0.4% | – | 38.4% | 15.2x | 10.0x | – | |
| STVNStevanato Group S.p.A. | $3.71B | +2.7% | +8.3% | 29.1% | 23.9x | 12.0x | – | |
| 同行中位数 | – | – | +5.8% | 32.6% | 22.9x | 12.3x | 26.3x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-09-30 Q3 2026 | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.7B | $1.69B | $1.58B | $1.66B | $1.62B | $1.68B | $1.58B | $1.69B |
| Gross Margin | 31.5% | 31.7% | 31.7% | 31.5% | 32.4% | 32.9% | 33.8% | 33.4% |
| Operating Margin | 8.2% | 7.2% | 7.3% | 7.6% | -40% | 7.7% | 9.3% | 37.8% |
| Net Income | $203.4M | $38.1M | $43.3M | $52.4M | $-711.8M | $64.7M | $64.5M | $500.4M |
| Diluted EPS | 0.3 | 0.06 | 0.06 | 0.08 | -1.04 | 0.09 | 0.09 | 0.73 |
| Operating Cash Flow | $195.1M | $178.2M | $58.7M | $152.7M | $207.4M | $154.4M | $109.3M | $173.3M |